Impact of NFIB and CYP1A variants on clozapine serum concentration—A retrospective naturalistic cohort study on 526 patients with known smoking habits

9Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Clinical response of clozapine is closely associated with serum concentration. Although tobacco smoking is the key environmental factor underlying interindividual variability in clozapine metabolism, recent genome-wide studies suggest that CYP1A and NFIB genetic variants may also be of significant importance, but their quantitative impact is unclear. We investigated the effects of the rs2472297 C>T (CYP1A) and rs28379954 T>C (NFIB) polymorphisms on serum concentrations in smokers and nonsmokers. The study retrospectively included 526 patients with known smoking habits (63.7% smokers) from a therapeutic drug monitoring service in Norway. Clozapine dose-adjusted concentrations (C/D) and patient proportions with subtherapeutic levels (<1070 nmol/L) were compared between CYP1A/NFIB variant allele carriers and homozygous wild-type carriers (noncarriers), in both smokers and nonsmokers. Clozapine C/D was reduced in patients carrying CYP1A-T and NFIB-C variants versus noncarriers, both among smokers (−48%; p < 0.0001) and nonsmokers (−35%; p = 0.028). Patients who smoke carrying CYP1A-T and NFIB-C variants had a 66% reduction in clozapine C/D versus nonsmoking noncarriers (p < 0.0001). The patient proportion with subtherapeutic levels was 2.9-fold higher in patients who smoke carrying NFIB-C and CYP1A-T variants versus nonsmoking noncarriers (p < 0.0001). In conclusion, CYP1A and NFIB variants have significant and additive impact on clozapine dose requirements for reaching target serum concentrations. Patients who smoke carrying the studied CYP1A and NFIB variants, comprising 2.5% of the study population, may need threefold higher doses to prevent risk of clozapine undertreatment. The results suggest that pre-emptive genotyping of NFIB and CYP1A may be utilized to guide clozapine dosing and improve clinical outcomes in patients with treatment-resistant schizophrenia.

References Powered by Scopus

LDlink: A web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants

1370Citations
N/AReaders
Get full text

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

1088Citations
N/AReaders
Get full text

Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer

1056Citations
N/AReaders
Get full text

Cited by Powered by Scopus

How Real-World Data Can Facilitate the Development of Precision Medicine Treatment in Psychiatry

9Citations
N/AReaders
Get full text

Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment

6Citations
N/AReaders
Get full text

Predicting clozapine dose required to achieve a therapeutic plasma concentration – A comparison of a population algorithm and three algorithms based on gene variant models

3Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Lenk, H. Ç., Løvsletten Smith, R., O’Connell, K. S., Jukić, M. M., Kringen, M. K., Andreassen, O. A., … Molden, E. (2023). Impact of NFIB and CYP1A variants on clozapine serum concentration—A retrospective naturalistic cohort study on 526 patients with known smoking habits. Clinical and Translational Science, 16(1), 62–72. https://doi.org/10.1111/cts.13422

Readers over time

‘22‘23‘24036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

75%

Professor / Associate Prof. 1

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

50%

Pharmacology, Toxicology and Pharmaceut... 2

50%

Save time finding and organizing research with Mendeley

Sign up for free
0